A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients _ GMMG-CONCEPT

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511791-32-00

Acronym

GMMG-CONCEPT

Enrollment

246

Registered

2024-09-16

Start date

2017-08-15

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

MRD negativity (sensitivity 10^-5, NGF) after consolidaton

Detailed description

Progression free survival

Interventions

DRUGRevlimid 10 mg hard capsules

DRUGRevlimid 25 mg hard capsules

DRUGKyprolis 60 mg powder for solution for infusion

DRUGRevlimid 15 mg hard capsules

DRUGSARCLISA 20mg/mL concentrate for solution for infusion.

DRUGRevlimid 5 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
MRD negativity (sensitivity 10^-5, NGF) after consolidaton	—

Secondary

Measure	Time frame
Progression free survival	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026